Glucose-like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients with Cirrhosis and Diabetes

Hepatology

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study

Nutr Metab Cardiovasc Dis

Morieri ML, Targher G, Lapolla A, D'Ambrosio M, Tadiotto F, Rigato M, Frison V, Paccagnella A, Simioni N, Avogaro A, Fadini GP

doi: 10.1016/j.numecd.2021.08.049

Further Publications

Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Hepatology

van Dalem J, Driessen JHM, Burden AM, Stehouwer CDA, Klungel OH, de Vries F, Brouwers MCGJ

doi: 10.1002/hep.32012

Hepatology

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

doi: 10.1002/hep.30368.

HepatitisHepatology

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Clin Gastroenterol Hepatol.

Chang ML, Cheng JS, Chien RN, Liaw YF

doi: 10.1016/j.cgh.2020.01.018.

Hepatology

Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis

Clin Gastroenterol Hepatol.

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Eslam M, Lai-Hung Wong G, George J, Romero-Gomez M, Adams LA

doi: 10.1016/j.cgh.2020.04.083.

Further Publications

Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B

Clin Gastroenterol Hepatol

Lee HW, Cheuk-Fung Yip T, Tse YK, Lai-Hung Wong G, Kim BK, Kim SU, Park JY, Kim DY, Lik-Yuen Chan H, Ahn SH, Wai-Sun Wong V

doi: 10.1016/j.cgh.2020.08.064

HepatitisHepatology

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Lancet Gastroenterol Hepatol

Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S

doi: 10.1016/S2468-1253(21)00031-5

HepatitisHepatology

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial

J Hepatol.

Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F

doi: 10.1016/j.jhep.2019.10.020.

Hepatitis

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries

J Viral Hepat.

Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R

doi: 10.1111/jvh.

Related content

Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study

Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis

Hepatitis flare-related decompensation is associated with better outcomes in patients with chronic hepatitis B

Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis

Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries